Translocations Flashcards
1
Q
t(12;21)
A
- B-ALL: ETV6 (12) and RUNX1 (21) translocation (aka. TEL-AML1)
- Accounts for 25% of all B-ALL and associated with a good prognosis
2
Q
t(9;22)
A
- B-ALL and CML: BCR (22) and ABL1 (9) translocation
- Historically dismal outcomes in B-ALL. Intermediate outcomes with TKIs
- Defining lesion of CML
- Of note, t(9;22) also translocation of extraskeletal myxoid chondrosarcoma- EWS (22) and CHN (9)
3
Q
11q23 Fusions
A
- Infantile ALL and AML commonly M4/M5: KMT2A (11; aka. MLL)
4
Q
t(8;14)
A
- Burkitt’s lymphoma/leukemia: cMYC (8) and IGH (14) translocation
- Found in 80% of Burkitt’s lymphoma
- Other translocations with the κ light (2) or λ light chain promoter (22) also occur but are less common
5
Q
t(8;21)
A
- AML M2: RUNX1 (21) and RUNX1T1 (8) translocation (aka. AML1-ETO)
- Core Binding Factor-related AML
- Found most commonly in FAB M2 (AML with maturation)
6
Q
inv(16)
A
- AML M4eo: Inversion leads to fusion of CBFB (16) and MYH11 (16)
- Core Binding Factor-related AML
- Found most commonly in FAB M4eo (AML with eosinophilia)
7
Q
t(15;17)
A
- AML M3: PML (15) and RARa (17) translocation
- Associated with AML M3 (APML)
8
Q
t(1;13)
A
ARMS: PAX7 (1) and FOXO1 (13; aka. FKHR) translocation
9
Q
t(2;13)
A
ARMS: PAX3 (2) and FOXO1 (13; aka. FKHR) translocation
10
Q
t(11;22)
A
Ewing’s Sarcoma
11
Q
del(5q)
A
- MDS/AML: Deletion of 5q
- Can be seen at the initial presentation in AML with MDS-related changes
- Therapy-related AML: After exposure to alkylating agents or radiation
12
Q
del(7q)
A
- MDS/AML: Deletion of 7q
- Can be seen at the initial presentation in AML with MDS-related changes
- Therapy-related AML: After exposure to alkylating agents or radiation
13
Q
del(X), del(Y)
A
- Ph-like ALL: Creates a P2RY8-CRLF2 fusion and upregulates CRLF2
- More common in Hispanic adolescents
- Of note, CRLF2 is located on both the X and Y chromosome in homologous pseudoautosomal
regions (PARs)
14
Q
iAMP(21)
A
- B-ALL: Internal amp of chr 21 leading to ≥3 copies of RUNX1
- Accounts for <2% of B-ALL
- Associated with worse outcomes
15
Q
t(1;19)
A
- B-ALL: TCF3 (19) and PBX1 (1) translocation (aka. E2A-PBX1)
- Accounts for 5% of B-ALL
- Historically associated with poor prognosis, but now intermediate outcomes on modern protocols with intensified chemotherapy
16
Q
t(1;22)
A
- AMKL: RBM15 (1; aka. OTT) and MKL1 (22) translocation
- Account for 10% of non-Down syndrome AMKL
17
Q
t(10;11)
A
- AML: KMT2A (11q23) and AF10 (10)
- Mostly seen in AML FAB M4/M5 (myelomonocytic/monocytic)